Carregant...
CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy
New advances in the design and manufacture of monoclonal antibodies, bispecific T cell engagers, and antibody-drug conjugates make the antibody-directed agents more powerful with less toxicities. Small molecule inhibitors are routinely used now as oral targeted agents for multiple cancers. The disco...
Guardat en:
| Publicat a: | J Hematol Oncol |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6842223/ https://ncbi.nlm.nih.gov/pubmed/31703740 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-019-0819-1 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|